These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35116455)

  • 1.
    Xue D; Lin H; Lin L; Wei Q; Yang S; Chen X
    Transl Cancer Res; 2021 Mar; 10(3):1284-1294. PubMed ID: 35116455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape and prognosis of patients with
    Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
    Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
    Cheng X; Yin H; Fu J; Chen C; An J; Guan J; Duan R; Li H; Shen H
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1027-1035. PubMed ID: 30810839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma.
    Ying K; Zou L; Wang D; Wang R; Qian J
    Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37904553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
    Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
    Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the
    Zou S; Ye J; Hu S; Wei Y; Xu J
    Int J Gen Med; 2022; 15():19-31. PubMed ID: 35018111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
    Liu B; Liu Y; Zou J; Zou M; Cheng Z
    Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
    Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
    Freudenstein D; Litchfield C; Caramia F; Wright G; Solomon BJ; Ball D; Keam SP; Neeson P; Haupt Y; Haupt S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic
    Fang Z; Wu X; Xiao L; Wang C; Zhao Y; Zhang Q; Jablonska PA; La Rosa A; Dempke WCM; Furqan M; Fan H
    J Thorac Dis; 2024 May; 16(5):3338-3349. PubMed ID: 38883659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.